S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
Log in
ETR:EVT

Evotec SE (EVT.F) Stock Forecast, Price & News

€33.02
+3.00 (+9.99 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
€30.49
Now: €33.02
€33.18
50-Day Range
€26.28
MA: €28.92
€30.35
52-Week Range
€17.17
Now: €33.02
€31.00
Volume3.45 million shs
Average Volume1.36 million shs
Market Capitalization$5.40 billion
P/E Ratio358.91
Dividend YieldN/A
BetaN/A
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. Its EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., Secarna Pharmaceuticals GmbH & Co. KG, and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; a strategic collaboration with Ildong Pharmaceutical Co., Ltd.; a drug discovery research collaboration with HitGen Inc.; a partnership with Rappta Therapeutics; and a partnership with Sartorius. The company was founded in 1993 and is headquartered in Hamburg, Germany.
Evotec SE (EVT.F) logo

MarketRank

Overall MarketRank

0.90 out of 5 stars

Analyst Opinion: 1.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-40-560810
Employees3,444
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$485.49 million
Cash Flow€1.90 per share
Book Value€3.12 per share

Profitability

Miscellaneous

Market Cap$5.40 billion
Next Earnings Date3/25/2021 (Estimated)
OptionableNot Optionable
€33.02
+3.00 (+9.99 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVT News and Ratings via Email

Sign-up to receive the latest news and ratings for EVT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Evotec SE (EVT.F) (ETR:EVT) Frequently Asked Questions

How has Evotec SE (EVT.F)'s stock price been impacted by COVID-19 (Coronavirus)?

Evotec SE (EVT.F)'s stock was trading at €20.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EVT stock has increased by 58.8% and is now trading at €33.02.
View which stocks have been most impacted by COVID-19
.

Is Evotec SE (EVT.F) a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evotec SE (EVT.F) in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Evotec SE (EVT.F) stock.
View analyst ratings for Evotec SE (EVT.F)
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Evotec SE (EVT.F)?

Wall Street analysts have given Evotec SE (EVT.F) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evotec SE (EVT.F) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Evotec SE (EVT.F)'s next earnings date?

Evotec SE (EVT.F) is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for Evotec SE (EVT.F)
.

What price target have analysts set for EVT?

5 equities research analysts have issued 1 year price targets for Evotec SE (EVT.F)'s shares. Their forecasts range from €29.00 to €33.00. On average, they expect Evotec SE (EVT.F)'s stock price to reach €32.00 in the next year. This suggests that the stock has a possible downside of 3.1%.
View analysts' price targets for Evotec SE (EVT.F)
or view Wall Street analyst' top-rated stocks.

Who are some of Evotec SE (EVT.F)'s key competitors?

What other stocks do shareholders of Evotec SE (EVT.F) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec SE (EVT.F) investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven Pharmaceutical (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC).

Who are Evotec SE (EVT.F)'s key executives?

Evotec SE (EVT.F)'s management team includes the following people:
  • Dr. Werner Lanthaler M.B.A., MBA, MPA, CEO & Member of Management Board (Age 53, Pay $997k)
  • Mr. Enno Spillner, CFO & Member of Management Board (Age 51, Pay $540k)
  • Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 57, Pay $614k)
  • Dr. Craig Johnstone, COO, Head of EVT Execute segment & Member of Management Board
  • Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting
  • Gabriele Hansen, Sr. VP Corp. Communications, Marketing & Investor Relations
  • Ms. Monika Conradt, Global Head of HR
  • Dr. Ian M. Hunneyball, Sr. VP of Programme Management & Clinical Operations (Age 71)
  • Dr. David Hallet, Exec. VP
  • Dr. Erich F. Greiner, Chief Innovation Officer (Age 55)

What is Evotec SE (EVT.F)'s stock symbol?

Evotec SE (EVT.F) trades on the ETR under the ticker symbol "EVT."

What is Evotec SE (EVT.F)'s stock price today?

One share of EVT stock can currently be purchased for approximately €33.02.

How big of a company is Evotec SE (EVT.F)?

Evotec SE (EVT.F) has a market capitalization of $5.40 billion and generates $485.49 million in revenue each year. Evotec SE (EVT.F) employs 3,444 workers across the globe.

What is Evotec SE (EVT.F)'s official website?

The official website for Evotec SE (EVT.F) is www.evotec.com.

How can I contact Evotec SE (EVT.F)?

Evotec SE (EVT.F)'s mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The company can be reached via phone at +49-40-560810.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.